Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze.

The gross margin held steady at 89%. CEO Bruce Cozadd said Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.

• Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox ...

Full story available on Benzinga.com